Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Abstract Text:

    ekaterina dadachovaEkaterina Dadachova,mahesh c patelMahesh C Patel,sima toussiSima Toussi,christos apostolidisChristos Apostolidis,alfred morgensternAlfred Morgenstern,martin w brechbielMartin W Brechbiel,miroslaw k gornyMiroslaw K Gorny,susan zolla-paznerSusan Zolla-Pazner,arturo casadevallArturo Casadevall,harris goldsteinHarris Goldstein,

    BACKGROUND: The HIV epidemic is a major threat to health in the developing and western worlds. A modality that targets and kills HIV-1-infected cells could have a major impact on the treatment of acute exposure and the elimination of persistent reservoirs of infected cells. The aim of this proof-of-principle study was to demonstrate the efficacy of a therapeutic strategy of targeting and eliminating HIV-1-infected cells with radiolabeled antibodies specific to viral proteins in vitro and in vivo. METHODS AND FINDINGS: Antibodies to HIV-1 envelope glycoproteins gp120 and gp41 labeled with radioisotopes bismuth 213 ((213)Bi) and rhenium 188 ((188)Re) selectively killed chronically HIV-1-infected human T cells and acutely HIV-1-infected human peripheral blood mononuclear cells (hPBMCs) in vitro. Treatment of severe combined immunodeficiency (SCID) mice harboring HIV-1-infected hPBMCs in their spleens with a (213)Bi- or (188)Re-labeled monoclonal antibody (mAb) to gp41 resulted in a 57% injected dose per gram uptake of radiolabeled mAb in the infected spleens and in a greater than 99% elimination of HIV-1-infected cells in a dose-dependent manner. The number of HIV-1-infected thymocytes decreased 2.5-fold in the human thymic implant grafts of SCID mice treated with the (188)Re-labeled antibody to gp41 compared with those treated with the (188)Re-control mAb. The treatment did not cause acute hematologic toxicity in the treated mice. CONCLUSIONS: The current study demonstrates the effectiveness of HIV-targeted radioimmunotherapy and may provide a novel treatment option in combination with highly active antiretroviral therapy for the eradication of HIV.

    Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Publishing Authors By Initials

    e dadachovaE Dadachova,mc patelMC Patel,s toussiS Toussi,c apostolidisC Apostolidis,a morgensternA Morgenstern,mw brechbielMW Brechbiel,mk gornyMK Gorny,s zolla-paznerS Zolla-Pazner,a casadevallA Casadevall,h goldsteinH Goldstein,

    For similar proteins: viral proteins research abstracts see: proteins: viral proteins research

    PUBMED ID PMID:

    MEDLINE DATE:

    Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Journal Published:

    PUBLICATION TYPE: Research Support, U.S. Gov't,

    Journal: PLoS medicine

    VOLUME: 3

    Page Numbers: e427

    Journal Abbreviation: PLoS Med.

    ISSN: 1549-1676

    DAY: 3

    MONTH: Nov

    YEAR: 2006

    Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 101231360

    Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Keywords Mesh Terms:

    KEYWORDS: Viral Proteins

    MESH TERMS: immunology

    Chemical & Substance for Abstract: Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. Information

    Substance Name: Bismuth

    Registry Number: 7440-69-9

    Grant and Affiliation Information for Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

    AFFILIATION: Albert Einstein College of Medicine, Bronx, New York, United States of America. edadacho@aecom.yu.edu

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NIAID

    GRANT: R01 AI48466

    ACRONYM: AI

    MEDLINETA: PLoS Med

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News